​​

Trademark Cases

Judicial Review of TMOB’s Decision Dismissed; Court Awards Elevated Costs for Applicant’s New and Inappropriate Argument
Cohen v. Susan Fiedler Incorporated,
2014 FC 967

This was a judicial review of a Trade-marks Opposition Board (“TMOB”) decision dismissing the Applicant’s application for registration of the “F CANCER & Design” trademark (the “Applicant’s Mark”). The Applicant, Ms. Cohen, claimed use of the mark  in Canada since September 2008 in association with t-shirts and a charitable foundation. The Respondent, however, asserted unregistered trademark rights to a family of trademarks, including “F CANCER”, “F* CANCER”, “F--- CANCER” and an additional (objectionable) trademark (collectively the “Opponent’s Marks”), and that they had been used in Canada since May 2008 in association with jewelery and fundraising charities.

The TMOB dismissed the Applicant’s application on the basis that the Respondent had established that the Opponent’s Marks had been used in Canada prior to the claimed date of first use of the Applicant’s Mark. In addition, the TMOB found that the Applicant had not demonstrated that there was no reasonable likelihood of confusion between the two Marks. Before the Court, the Applicant did not take issue with those findings, but instead raised a new argument: that the Respondent was in fact prohibited from using [the “F” word] since it is obscene and therefore contrary to s.9(1)(j) of the Trademarks Act. The Court characterized the Applicant’s argument as “counter-intuitive”, since if it had been accepted, would have been fatal to her application. The Court exercised its discretion not to consider this argument since it was raised for the first time on judicial review, and was, in the Court’s view, inappropriate. The Court therefore dismissed the Applicant’s application for judicial review and awarded elevated costs to the Respondent in light of the Applicant’s novel argument on judicial review.

Industry News

Health Canada has published a new Draft Guidance for Sponsors: Preparation of Clinical Trial Applications for use of Cell Therapy Products in Humans. The consultation period is open until December 6, 2014.

The BLG Life Sciences Group has published LIFESIGNS: Life Sciences Legal Trends in Canada, a Report on Intellectual Property, Litigation, Corporate Commercial legal trends and industry developments in Canada.

Authors

Chantal Saunders 
CSaunders@blg.com
613.369.4783

Adrian J. Howard 
AJHoward@blg.com
613.787.3557

Beverley Moore 
BMoore@blg.com
613.369.4784

Expertise

Intellectual Property
Trade-marks
Patents
Licensing
Copyright